Miller-Fisher Syndrome: Are Anti-GAD Antibodies Implicated in Its Pathophysiology?
| Autor: | Ourania Argyropoulou, Sevasti Bostantjopoulou, Ioannis E. Dagklis, Varvara Theodoridou, Dimitrios Kazis, Sotirios Papagiannopoulos |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Ataxia biology business.industry Glutamate decarboxylase Case Report Gamma globulin lcsh:RC346-429 Pathophysiology 03 medical and health sciences Titer Anti gad antibodies 030104 developmental biology 0302 clinical medicine Immunology biology.protein medicine Miller-Fisher syndrome Antibody medicine.symptom General Agricultural and Biological Sciences business lcsh:Neurology. Diseases of the nervous system 030217 neurology & neurosurgery |
| Zdroj: | Case Reports in Neurological Medicine, Vol 2016 (2016) Case Reports in Neurological Medicine |
| ISSN: | 2090-6676 2090-6668 |
| DOI: | 10.1155/2016/3431849 |
| Popis: | Miller-Fisher syndrome (MFS) is considered as a variant of the Guillain-Barre syndrome (GBS) and its characteristic clinical features are ophthalmoplegia, ataxia, and areflexia. Typically, it is associated with anti-GQ1b antibodies; however, a significant percentage (>10%) of these patients are seronegative. Here, we report a 67-year-old female patient who presented with the typical clinical features of MFS. Workup revealed antibodies against glutamic acid decarboxylase (GAD) in relatively high titers while GQ1b antibodies were negative. Neurological improvement was observed after intravenous gamma globulin and follow-up examinations showed a continuous clinical amelioration with simultaneous decline of anti-GAD levels which finally returned to normal values. This case indicates that anti-GAD antibodies may be associated with a broader clinical spectrum and future studies in GQ1b-seronegative patients could determine ultimately their clinical and pathogenetic significance in this syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|